TrialArthritis & rheumatology (Hoboken, N.J.)2021

The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.

Aaron Winkler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.